Key result
EPICOR Asia registry details two-year real-world antithrombotic management patterns and outcomes in ACS survivors.
Why the study?
In-hospital and postdischarge mortality for ACS vary across Asia and remain generally poorer than globally, with unclear relationships between real-life antithrombotic management patterns and ACS outcomes.
Observational (n=12,922)
Yes
The EPICOR Asia study will provide large-scale, real-world data on antithrombotic management patterns and their impact on clinical outcomes in ACS patients across Asia.
Real-world antithrombotic patterns in Asian ACS survivors extend regional data; should not yet change practice pending outcomes.
BACKGROUND: In-hospital and postdischarge mortality for acute coronary syndromes (ACS) vary across Asia and remain generally poorer than globally. The relationship between real-life antithrombotic management patterns (AMPs) and ACS-related outcomes in Asia is unclear. METHODS: EPICOR Asia (Long-tErm follow-uP of antithrombotic management patterns In acute CORonary syndrome patients in Asia) (NCT01361386) is a prospective, multinational, observational study of patients discharged after hospitalization for an ACS, with 2-year follow-up. The aim is to describe short- and long-term (up to 2 years post-index event) AMPs in patients hospitalized for ACS and to record clinical outcomes, healthcare resource use, and self-reported health status. Pre- and in-hospital management, AMPs, and associated outcomes, with particular focus on ischemic and bleeding events, will be recorded during the 2-year follow up. RESULTS: Between June 2011 and May 2012, 13 005 patients were enrolled. From these, 12 922 patients surviving an ACS (6616 with STEMI, 2570 with NSTEMI, and 3736 with UA) were eligible for inclusion from 219 hospitals across 8 countries and regions in Asia: China (n = 8214), Hong Kong (n = 177), India (n = 2468), Malaysia (n = 100), Singapore (n = 93), South Korea (n = 705), Thailand (n = 957), and Vietnam (n = 208). CONCLUSIONS: EPICOR Asia will provide information regarding clinical management and AMPs for ACS patients in Asia. Impact of AMPs on clinical outcomes, healthcare resource use, and self-reported health status both during hospitalization and up to 2 years after discharge will also be described.
No takes yet. Share an insight, caveat, or question.
Huo et al. (2015) conducted an observational in Acute Coronary Syndromes (n=12,922). Antithrombotic management patterns was evaluated on Clinical outcomes, healthcare resource use, and self-reported health status (focusing on ischemic and bleeding events). The EPICOR Asia observational study enrolled 12,922 patients surviving an acute coronary syndrome across 8 Asian countries to evaluate antithrombotic management patterns over a 2-year follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: